Volatility and Risk
Avenue Therapeutics has a beta of 0.04, indicating that its share price is 96% less volatile than the S&P 500. Comparatively, Ceapro has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500.
Institutional and Insider Ownership
17.3% of Avenue Therapeutics shares are held by institutional investors. 1.8% of Avenue Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Avenue Therapeutics and Ceapro’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Avenue Therapeutics | N/A | -471.57% | -296.50% |
| Ceapro | -69.60% | -20.30% | -18.07% |
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Avenue Therapeutics | N/A | N/A | -$10.38 million | ($0.95) | -0.74 |
| Ceapro | $7.14 million | 1.86 | -$3.49 million | ($0.06) | -2.83 |
Ceapro has higher revenue and earnings than Avenue Therapeutics. Ceapro is trading at a lower price-to-earnings ratio than Avenue Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Ceapro beats Avenue Therapeutics on 6 of the 10 factors compared between the two stocks.
About Avenue Therapeutics
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.
About Ceapro
Ceapro Inc., a biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally. The company is involved in the development of proprietary extraction technologies and the application of these technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries. It also offers natural active ingredients, including oat powder, oat oil, oat peptides, and lupin peptides to the personal care, cosmetic, medical, and animal health industries; anti-aging skincare products to the cosmeceutical industries; and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner. The company has a research collaboration with the Angiogenesis Foundation. The company was incorporated in 1997 and is headquartered in Edmonton, Canada.
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
